Last updated on February 2018

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Brief description of study

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

Clinical Study Identifier: NCT02355535

Contact Investigators or Research Sites near you

Start Over

Oana Danciu, MD

University of Illinois at Chicago
Chicago, IL United States
  Connect »

Matthias Holdhoff, MD, PhD

Johns Hopkins Kimmel Cancer Center
Baltimore, MD United States
  Connect »

Richard Peterson, MD

Regions Hospital
Saint Paul, MN United States
  Connect »